Drug Type Small molecule drug |
Synonyms- |
Target |
Action inhibitors |
Mechanism NLRP3 inhibitors(NACHT, LRR and PYD domains-containing protein 3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC21H24N2O2 |
InChIKeyFNGGIPWAZSFKCN-ACRUOGEOSA-N |
CAS Registry4429-63-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | Preclinical | China | 28 Feb 2024 | |
Inflammation | Discovery | China | 10 Jan 2023 |